Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02375464|
Expanded Access Status : No longer available
First Posted : March 2, 2015
Last Update Posted : November 8, 2016
|Condition or disease||Intervention/treatment|
|Neuroendocrine Tumors||Drug: Gallium-68 DOTATOC|
Patients with NETs will be evaluated by their own physicians. Before doing the PET scan using Gallium-68 DOTATOC, the physicians will be asked to describe the type of treatment that they would recommend. After the test is performed and the result reviewed, the physician will be asked to reevaluate the therapeutic and management options. Data will be analyzed to determine the impact of the testing on patient management.
Gallium-68 has been designated an "orphan drug" due to the relative rarity of NETs. It is expected that the data collected from this and other similar trials will be used to provide data to the FDA regarding the safety and efficacy of this drug as an imaging agent for NETs and ultimately lead to FDA approval.
|Study Type :||Expanded Access|
|Official Title:||Gallium-68 DOTATOC for Management of Neuroendocrine Tumors|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2019|
- Drug: Gallium-68 DOTATOC
Imaging with Gallium-68 DOTATOCOther Name: Gallium-68 (DOTA0-Phe1-Tyr3)octreotide
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02375464
|Principal Investigator:||STEPHEN C SCHARF, MD||Lenox Hill Hospital|